Search Results
Search for other papers by James C Yao in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Marianne E Pavel in
Google Scholar
PubMed
Search for other papers by Emily Bergsland in
Google Scholar
PubMed
Search for other papers by Philippe Ruszniewski in
Google Scholar
PubMed
Search for other papers by Daniel M Halperin in
Google Scholar
PubMed
Search for other papers by Daneng Li in
Google Scholar
PubMed
Search for other papers by Salvatore Tafuto in
Google Scholar
PubMed
Search for other papers by Nitya Raj in
Google Scholar
PubMed
Search for other papers by Davide Campana in
Google Scholar
PubMed
Search for other papers by Susumu Hijioka in
Google Scholar
PubMed
Search for other papers by Markus Raderer in
Google Scholar
PubMed
Search for other papers by Rosine Guimbaud in
Google Scholar
PubMed
Search for other papers by Pablo Gajate in
Google Scholar
PubMed
Search for other papers by Sara Pusceddu in
Google Scholar
PubMed
Search for other papers by Albert Reising in
Google Scholar
PubMed
Search for other papers by Evgeny Degtyarev in
Google Scholar
PubMed
Search for other papers by Mark Shilkrut in
Google Scholar
PubMed
Search for other papers by Simantini Eddy in
Google Scholar
PubMed
Search for other papers by Simron Singh in
Google Scholar
PubMed
every 30 days up to 150 days following the last dose, or until the start of subsequent antineoplastic medication between 30 and 150 days after the last dose. The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 and EQ-5D-5L
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Andreas Venizelos in
Google Scholar
PubMed
Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Trondheim, Norway
Search for other papers by Hege Elvebakken in
Google Scholar
PubMed
Search for other papers by Aurel Perren in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Oleksii Nikolaienko in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Wei Deng in
Google Scholar
PubMed
Search for other papers by Inger Marie B Lothe in
Google Scholar
PubMed
Search for other papers by Anne Couvelard in
Google Scholar
PubMed
Search for other papers by Geir Olav Hjortland in
Google Scholar
PubMed
Department of Medical Radiation Physics, Lund University, Lund, Sweden
Search for other papers by Anna Sundlöv in
Google Scholar
PubMed
Search for other papers by Johanna Svensson in
Google Scholar
PubMed
Search for other papers by Harrish Garresori in
Google Scholar
PubMed
Search for other papers by Christian Kersten in
Google Scholar
PubMed
Department of Oncology, St.Olavs Hospital, Trondheim, Norway
Search for other papers by Eva Hofsli in
Google Scholar
PubMed
Department of Clinical Medicine, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark
Search for other papers by Sönke Detlefsen in
Google Scholar
PubMed
Search for other papers by Merete Krogh in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Oncology, Haukeland University Hospital, Bergen, Norway
Search for other papers by Stian Knappskog in
Google Scholar
PubMed
included for the present analyses (see Supplementary Methods for details, see section on supplementary materials given at the end of this article). Histological sections (HE, CgA, synaptophysin, Ki-67) were collected, digitalized and subjected to a
Search for other papers by Himisha Beltran in
Google Scholar
PubMed
Search for other papers by Francesca Demichelis in
Google Scholar
PubMed
et al. 2017 , Mu et al. 2017 ), and homeobox genes (eg. HOXB5, HOXB6) ( He et al. 2021 ), as well as dysregulation of prostate cancer genes in the context of AR therapy (eg. ERG, SPINK1) ( Mounir et al. 2015 , Tiwari et al. 2020 ), and
Search for other papers by Ha Nguyen in
Google Scholar
PubMed
Search for other papers by Komal Shah in
Google Scholar
PubMed
Search for other papers by Steven G Waguespack in
Google Scholar
PubMed
Search for other papers by Mimi I Hu in
Google Scholar
PubMed
Search for other papers by Mouhammed Amir Habra in
Google Scholar
PubMed
Search for other papers by Maria E Cabanillas in
Google Scholar
PubMed
Search for other papers by Naifa L Busaidy in
Google Scholar
PubMed
Search for other papers by Roland Bassett in
Google Scholar
PubMed
Search for other papers by Shouhao Zhou in
Google Scholar
PubMed
Search for other papers by Priyanka C Iyer in
Google Scholar
PubMed
Search for other papers by Garrett Simmons in
Google Scholar
PubMed
Search for other papers by Diana Kaya in
Google Scholar
PubMed
Search for other papers by Marie Pitteloud in
Google Scholar
PubMed
Search for other papers by Sumit K Subudhi in
Google Scholar
PubMed
Search for other papers by Adi Diab in
Google Scholar
PubMed
Search for other papers by Ramona Dadu in
Google Scholar
PubMed
. One patient (1/19, 5%) had isolated central hypothyroidism without MRI changes. This patient received thyroid hormone replacement and high-dose steroids. At 2 year follow-up, he remained on thyroid hormone. Six patients (6/19, 32%) had isolated central
Search for other papers by J T W Kwon in
Google Scholar
PubMed
Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
Search for other papers by R J Bryant in
Google Scholar
PubMed
Search for other papers by E E Parkes in
Google Scholar
PubMed
radiotherapy with concomitant androgen deprivation therapy (ADT). However, despite early-stage disease having a 5-year relative survival rate of approximately 100%, patient survival drops markedly to around 30% once PCa has disseminated ( Siegel et al. 2020
Search for other papers by Justine Vanhevel in
Google Scholar
PubMed
Search for other papers by Lieve Verlinden in
Google Scholar
PubMed
Search for other papers by Stefanie Doms in
Google Scholar
PubMed
Search for other papers by Hans Wildiers in
Google Scholar
PubMed
Search for other papers by Annemieke Verstuyf in
Google Scholar
PubMed
basal-like BC and has the worst prognosis of all BC subtypes. Basal-like BC is characterized by the expression of keratin 5, 14 and 17 and occurs mainly in young premenopausal women under the age of 40, accounting for 15–20% of BC diagnoses ( Yin et al
Search for other papers by Chi-Yu Kuo in
Google Scholar
PubMed
Search for other papers by Yuan-Ching Chang in
Google Scholar
PubMed
Search for other papers by Ming-Nan Chien in
Google Scholar
PubMed
Search for other papers by Jie-Yang Jhuang in
Google Scholar
PubMed
Search for other papers by Yi-Chiung Hsu in
Google Scholar
PubMed
Search for other papers by Shih-Yuan Huang in
Google Scholar
PubMed
Department of Medical Research, MacKay Memorial Hospital, Taipei, Taiwan
Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
Search for other papers by Shih-Ping Cheng in
Google Scholar
PubMed
consumption rate (OCR) and extracellular acidification rate (ECAR) of live thyroid cancer cells were determined using a Seahorse XF24 Analyzer (Agilent Technologies) using the Mito Stress Test Kit (Agilent) with 1 μM oligomycin, 1 μM FCCP, and 0.5 μM rotenone
Search for other papers by Livia Lamartina in
Google Scholar
PubMed
Search for other papers by Nadège Anizan in
Google Scholar
PubMed
Search for other papers by Corinne Dupuy in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
in differentiated thyroid cancers ( Fagin & Wells 2016 ). In the Thyroid Cancer Genome Atlas based on the analysis of 500 papillary thyroid cancer tissues, one driver alteration was found in 96.5% of tumors and these alterations were mutually